Herpetic Keratitis
Conditions
Keywords
acyclovir, ganciclovir
Brief summary
Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition
Interventions
DRUGAcyclovir 400 MG
Acyclovir is used to treat infections caused by certain types of viruses.
Ganciclovir is an anti-viral drug
Sponsors
Al-Azhar University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with herpetic keratitis
Exclusion criteria
* Patients with known allergies to ganciclovir or acyclovir * Severe ocular surface disease * Those who have previously received antiviral therapy for herpetic keratitis within the last month
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Corneal healing | At 4 and 6 weeks | Heling of the keratitis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sie effects | at 4 and 6 weeks | Measuring the percentage of the side effects of the drugs |
Countries
Egypt
Outcome results
None listed